Q-omics provides the consensus-scored KMT5C profile across patient tissues and cancer cell-line models. KMT5C expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KMT5C is differentially expressed in 17, with the highest sampling consensus in KIRP. Additionally, KMT5C RNA expression shows 19,437 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, KIRP, and UVM as cancer lineages where KMT5C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KMT5C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KMT5C survival associations across molecular data types. KMT5C RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KMT5C RNA expression–survival associations across cancer types. High KMT5C expression shows unfavorable associations in KIRC, ACC, SKCM, LGG and LIHC, but favorable associations in SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KMT5C RNA expression.
This table summarizes KMT5C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KMT5C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KMT5C shows higher tumor expression in KIRP, HNSC, KIRC, COAD, LIHC and BLCA. The KIRP box plot shows higher KMT5C RNA expression in tumor versus normal tissue (log2 FC = +1.562, t-test p < 0.001).
This table shows molecular features associated with KMT5C in patient tissues and cancer cell lines. In patient samples, KMT5C shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, KMT5C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
